Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis.

The Journal of dermatological treatment·2026
Same author

Comprehensive proteome profiling of molecular endotypes in Japanese adults with moderate-to-severe atopic dermatitis.

Frontiers in medicine·2025
Same author

Spatial profiling of giant cell arteritis tissues reveals immune heterogeneity and potential predictors of glucocorticoid response.

Annals of the rheumatic diseases·2025
Same author

Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial.

The Lancet. Rheumatology·2025
Same author

Regulation of fibroblast-like synoviocyte function by cadherin 6 in rheumatoid arthritis.

Arthritis research & therapy·2025
Same author

Lebrikizumab Rapidly Lowers Inflammatory Biomarkers with Clinical Correlations in Moderate-to-Severe Atopic Dermatitis.

Dermatology and therapy·2025

Related Experiment Video

Updated: Jul 10, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Tumor-derived death receptor 6 modulates dendritic cell development.

David C DeRosa1, Paul J Ryan, Angela Okragly

  • 1Eli Lilly and Company, BioTherapeutic Discovery Research, Indianapolis, IN 46285, USA.

Cancer Immunology, Immunotherapy : CII
|October 27, 2007
PubMed
Summary

Tumor cells can evade immune detection by shedding Death Receptor 6 (DR6), which impairs the development of crucial antigen-presenting dendritic cells (DCs). This shedding is mediated by matrix metalloproteinase-14 (MMP-14).

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
09:51

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

Related Experiment Videos

Last Updated: Jul 10, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
09:51

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Cancer immune evasion is a major challenge in oncology.
  • Dendritic cells (DCs) are key players in initiating anti-tumor immune responses.
  • Death Receptor 6 (DR6) is implicated in immune regulation and is overexpressed in some cancers.

Purpose of the Study:

  • To investigate the role of DR6 in cancer immune evasion.
  • To determine if DR6 negatively impacts anti-tumor immunity by affecting DC generation.
  • To explore the mechanism of DR6 shedding and its consequences on DCs.

Main Methods:

  • Studied DR6 expression and shedding in cancer cell lines.
  • Investigated the effect of soluble DR6 on monocyte-derived DC differentiation and function.
  • Utilized murine models and human cancer patients' data.
  • Analyzed DC phenotype, cytokine production, and antigen presentation capacity.

Main Results:

  • DR6 is cleaved from tumor cell surfaces by matrix metalloproteinase-14 (MMP-14).
  • Soluble DR6 significantly inhibits the differentiation of monocytes into DCs (>50% cell death).
  • DR6 alters immature DC phenotype and cytokine profiles, impacting antigen presentation, though maturation partially restores function.

Conclusions:

  • MMP-14-mediated shedding of DR6 is a novel mechanism of tumor immune evasion.
  • This process compromises the generation and function of antigen-presenting cells (APCs).
  • Targeting the MMP-14/DR6 axis may represent a therapeutic strategy to enhance anti-tumor immunity.